Abstract

Background Many patients with acute coronary syndromes are offered percutaneous coronary intervention. However, the appropriate indications for, and optimal timing of, such procedures are uncertain. We analysed timing of intervention and associated events (death and myocardial infarction) in the PURSUIT trial in which 9461 patients received a platelet glycoprotein IIb/IIIa inhibitor, eptifibatide, or placebo for 72h. Other treatment was left to the investigators. 2430 patients underwent percutaneous coronary intervention within 30 days. Four groups were distinguished, who underwent percutaneous coronary intervention on day 1; on days 2 or 3; at 4 to 7 days; or between 8 until 30 days, for eptifibatide- and placebo-treated patients.

Results The four groups treated with placebo demonstrated total 30-day events of 15·9% for day 1 percutaneous coronary intervention, 17·7%, 15·0% and 18·2%, respectively, for successive intervals of later intervention. Later intervention was associated with more pre-procedural events (2·2% to 13·7%, P=0·001) which was balanced by a decrease in procedure-related events (12·1 to 3·1%, P=0·001), while the overall 30-day event rates were similar. Eptifibatide-treated patients with percutaneous coronary intervention on day 1 had the lowest rate of 30-day events (9·2%, P<0·05 vs other groups). In this group, pre-procedural risk was only 0·3%, while percutaneous coronary intervention on eptifibatide treatment was associated with low procedural risk (7·2%). The total 30-day event rate for later percutaneous coronary intervention in patients receiving eptifibatide was 14·0 on days 2 and 3, 15·0% for days 4 to 7 and 17·4% for days 7 to 30, respectively.

Conclusion Patients treated with a platelet glycoprotein IIb/IIIa receptor blocker, and early percutaneous coronary intervention (within 24h) had the lowest event rate in this post hoc analysis. Thus ‘watchful waiting’ may not be the optimal strategy. Rather an early invasive strategy with percutaneous coronary intervention under protection of a platelet glycoprotein IIb/IIIa receptor blocker should be considered in selected patients. Randomized trials are warranted to verify this issue.

f1
Correspondence: Prof Maarten L. Simoons, University Hospital Rotterdam, Thoraxcenter Cardiology, room H560, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

References

1
Braunwald
E
, Jones RH, Mark DB. Diagnosing and managing unstable angina.
Circulation
 .
1994
;
90
:
613
–622
2
Hillis
WS
. The continuing debate: conservative or interventional therapy for unstable coronary artery disease.
Am J Cardiol
 .
1997
;
80
:
51E
–54E
3
Theroux
P
, Fuster V. Acute coronary syndromes. Unstable angina and non-Q myocardial infarction.
Circulation
 .
1998
;
97
:
1195
–1206
4
Theroux
P
, White H, David D. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial.
Circulation
 .
1994
;
89
:
1545
–1556
5
Boden
WE
, O'Rourke RA, Crawford MH. Outcomes in patients with acute non-Q myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy.
N Engl J Med
 .
1998
;
338
:
1785
–1792
6
Lancet
 .
1999
;
354
:
708
–715
7
TACTICS TIMI-18 results were presented during the November 2000 annual sessions of the American Heart Association
8
Van Miltenburg-Van Zijl
AJM
, Simoons ML, Bossuyt PMM, Taylor TR, Veerhoek MJ. Variation in the use of coronary angiography in patients with unstable angina is related to differences in patient population and availability of angiography facilities, without affecting prognosis.
Eur Heart J
 .
1996
;
17
:
1828
–1835
9
Yusuf
S
, Flather M, Pogue J. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation.
Lancet
 .
1998
;
352
:
507
–514
10
De Feyter
PJ
, Suryapranata H, Serruys PW. Coronary Angioplasty for Unstable Angina: Immediate and Late Results in 200 Consecutive Patients With Identification of Risk Factors for Unfavorable Early and Late Outcome.
J Am Coll Cardiol
 .
1988
;
12
:
324
–333
11
Bentivoglio
LG
, Detre K, Yeh W, Williams DO, Kelsey SF, Faxon DP. Outcome of percutaneous transluminal coronary angioplasty in subsets of unstable angina pectoris. A report of the 1985–1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.
J Am Coll Cardiol
 .
1994
;
24
:
1195
–1206
12
Boersma
E
, Akkerhuis M, Theroux P. Platelet glycoprotein IIb/IIIa receptor inhibition in Non-ST-Elevation acute coronary syndromes. Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Circulation
 .
1999
;
100
:
2045
–2048
13
Ronner
E
, Dykun Y, Van den Brand MJBM, Van der Wieken LR, Simoons ML. Platelet glycoprotein IIb/IIIa receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention.
Eur Heart J
 .
1998
;
19
:
1608
–1616
14
N Engl J Med
 .
1998
;
339
:
436
–443
15
Harrington
RA
. Clinical trials in acute coronary syndromes: lessons from PURSUIT.
Eur Heart J
 .
1999
;
1
:
R28
–R34
16
Boersma
E
, Pieper KS, Steyerberg EW. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients.
Circulation
 .
2000
;
101
:
2557
–2567
17
Bertrand
ME
, Simoons ML, Fox KAA. Management of acute coronary syndromes: acute coronary syndromes without persistent ST-segment elevation. Recommendations of the task force of the European Society of Cardiology.
Eur Heart J
 .
2000
;
17
:
1406
–1432
18
Braunwald
E
, Antman EM, Beasley JW. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the ACC/AHA task force on practice guidelines.
Circulation
 .
2000
;
102
:
1193
–2009
19
Cohen
M
, Demers C, Gurfinkel EP. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary disease.
N Engl J Med
 .
1997
;
337
:
447
–452
20
Lancet
 .
1996
;
347
:
561
–568
21
Antman
EM
, McCabe CH, Gurfinkel EP. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction.
Circulation
 .
1999
;
100
:
1593
–1601
22
N Engl J Med
 .
1994
;
330
:
956
–961
23
N Engl J Med
 .
1997
;
336
:
1689
–1696
24
Lancet
 .
1998
;
352
:
87
–92
25
Lancet
 .
1997
;
349
:
1429
–1435
26
Lancet
 .
2000
;
356
:
2037
–2044

Comments

0 Comments